Suven Life Sciences Presents Samelisant Data at SLEEP-2026

Suven Life Sciences Limited announced the presentation of three posters at the SLEEP-2026 Annual Meeting in Baltimore, USA. The presentations focus on Samelisant (SUVN-G3031), a drug candidate for Central Nervous System disorders. Key highlights include Phase-2 efficacy data for excessive daytime sleepiness (EDS), the design of a Phase-2 study for cataplexy in Type 1 narcolepsy, and the Phase-3 development strategy for narcolepsy. The company also engaged with researchers, KOLs, and potential partners at their exhibit booth.